Short Interest in Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Grows By 546.9%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 951 shares, an increase of 546.9% from the February 26th total of 147 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 2,385 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International in the 3rd quarter valued at $383,000. XY Capital Ltd lifted its stake in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG boosted its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the period. ABC Arbitrage SA purchased a new stake in shares of Ascentage Pharma Group International in the third quarter worth about $204,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International in the third quarter valued at about $96,000.

Ascentage Pharma Group International Stock Up 0.5%

Shares of AAPG stock opened at $22.43 on Thursday. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a fifty-two week low of $17.56 and a fifty-two week high of $48.45. The firm’s 50 day moving average price is $24.22 and its two-hundred day moving average price is $30.05.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AAPG. Oppenheimer began coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective for the company. BTIG Research started coverage on Ascentage Pharma Group International in a report on Thursday, March 12th. They issued a “buy” rating and a $48.00 target price on the stock. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Finally, Rodman & Renshaw started coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to MarketBeat.com, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus target price of $48.00.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.